Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 25, pp. 2382-2393
Open Access | Times Cited: 438

Showing 1-25 of 438 citing articles:

KRAS mutation: from undruggable to druggable in cancer
Lamei Huang, Zhixing Guo, Fang Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 585
Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 529
Targeting p53 pathways: mechanisms, structures and advances in therapy
Haolan Wang, Ming Guo, Hudie Wei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 365
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 300
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona Yaeger, Jared Weiss, Meredith Pelster, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 44-54
Open Access | Times Cited: 288
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Dong-Sung Kim, Lorenz Herdeis, Dorothea Rudolph, et al.
Nature (2023) Vol. 619, Iss. 7968, pp. 160-166
Open Access | Times Cited: 253
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 246
Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 240
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Samantha B. Kemp, Noah Cheng, Nune Markosyan, et al.
Cancer Discovery (2022) Vol. 13, Iss. 2, pp. 298-311
Open Access | Times Cited: 220
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Joseph M. Chan, Samir Zaidi, Jillian Love, et al.
Science (2022) Vol. 377, Iss. 6611, pp. 1180-1191
Open Access | Times Cited: 202
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Marco H. Hofmann, Daniel Gerlach, Sandra Misale, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 924-937
Open Access | Times Cited: 195
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Hosein, Stephanie K. Dougan, Andrew J. Aguirre, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 272-286
Open Access | Times Cited: 175
Emerging strategies to target RAS signaling in human cancer therapy
Kun Chen, Yalei Zhang, Ling Qian, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 158
Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 155
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Albert K. Kwan, Gary A. Piazza, Adam B. Keeton, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 130
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 129
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao, et al.
Science (2023) Vol. 381, Iss. 6659, pp. 794-799
Open Access | Times Cited: 117
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Yanlin Song, Zhenfei Bi, Yu Liu, et al.
Genes & Diseases (2022) Vol. 10, Iss. 1, pp. 76-88
Open Access | Times Cited: 109
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1556-1571
Open Access | Times Cited: 103
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
Thijs J. Hagenbeek, Jason R. Zbieg, Marc Hafner, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 812-828
Open Access | Times Cited: 92
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 91
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
Ziyang Zhang, Peter J. Rohweder, Chayanid Ongpipattanakul, et al.
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 1060-1069.e7
Open Access | Times Cited: 91
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Matthew Holderfield, Bianca J. Lee, Jingjing Jiang, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 919-926
Open Access | Times Cited: 90
Page 1 - Next Page

Scroll to top